Hypercholesterolemia Drugs Market

Market Insights

Factors such as an increase in awareness of hypercholesterolemia and cardiovascular diseases, changing lifestyle patterns, an increase in the number of obese people, and a growing geriatric population are driving the growth of the hypercholesterolemia drugs market globally.

The report titled “Hypercholesterolemia Drugs Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” offers strategic insights into the overall hypercholesterolemia drugs market, along with the market size and estimates for the duration of 2015–2025. The research study covers an in-depth analysis of market segments based on drug class and different geographical regions.

Geographically, the global hypercholesterolemia drugs market is studied for the following regional markets:

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• Rest of Europe

Asia-Pacific

• China
• Japan
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Rest of LATAM

Middle East and Africa

• GCC
• the remainder of MEA

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global hypercholesterolemia drugs market.

Tools such as market positioning of key players, pipeline analysis, and an appealing investment proposition provide readers with insights into the global hypercholesterolemia drugs market’s competitive scenario. This report concludes with a company profiles section that highlights major information about the key players engaged in the global hypercholesterolemia drugs market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global hypercholesterolemia drugs market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

Based on drug class, the global hypercholesterolemia drugs market is segmented as follows:

• Statins/HMG-CoA Reductase Inhibitors
• Bile acid sequestrants
• Fibrates
• Inhibitors of Cholesterol Absorption
• Others

Hypercholesterolemia, also known as high cholesterol, is characterized by the presence of high levels of cholesterol in the body, which increases the risk of developing a heart attack or stroke. Some factors such as changing lifestyle patterns, rising healthcare awareness, an increase in the number of obese people, the growing incidence of hypercholesterolemia-related diseases, growing awareness about cardiovascular diseases, and a rising geriatric population are primarily driving the growth of the hypercholesterolemia drugs market globally.

For the purpose of the study, the hypercholesterolemia drugs market is segmented on the basis of drug class, such as HMG-CoA reductase inhibitors, bile acid sequestrants, fabric acid derivatives, cholesterol absorption inhibitors, and others. It has been determined that, among the market segments considered, statins are a significant revenue contributor because they are recommended for use in the management of hypercholesterolemia due to their safety and effectiveness. Furthermore, statins completely inhibit HMG-CoA reductase, which is responsible for cholesterol production; additionally, statins are involved in decreasing LDL cholesterol levels and increasing HDL cholesterol levels and are thus most preferred in the hypercholesterolemia market.

For the purpose of this study, the hypercholesterolemia drugs market is categorized into three categories:

• North America
• Europe
• Asia Pacific
• Latin America (LATAM)
• Middle East and Africa (MEA)

Among the considered market segments, North America dominated the global hypercholesterolemia market, and growth was primarily driven by the United States. Some factors, such as sedentary lifestyle patterns, higher cost of medication, a large number of target populations, increasing risk of cardiovascular diseases, and higher treatment awareness, are prime factors that are assisting the market’s growth in North America.

According to the Centers for Disease Control and Prevention (CDC), more than 73.5 million adults (31.7%) in the United States have high low-density lipoprotein. Nearly 31 million adult Americans, have a total cholesterol level greater than 240 mg/dL. According to the World Health Organization (WHO), more than half of adults in high-income countries had elevated total cholesterol, which was more than twice the level in low-income countries. It is estimated that Asia Pacific will show the highest growth during the forecast period due to rising healthcare awareness and changing lifestyle patterns that will influence the market growth of hypercholesterolemia drugs.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Hypercholesterolemia Drugs Market Snapshot
2.2 Global Hypercholesterolemia Drugs Market, by Drugs Class
2.3 Global Hypercholesterolemia Drugs Market Share, by Geography, 2016 (Value %)

Chapter 3 Hypercholesterolemia Drugs Market Analysis
3.1 Global Hypercholesterolemia Drugs Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Pipeline Analysis of Hypercholesterolemia Drugs
3.4 Guidelines for Management of Hypercholesterolemia
3.5 Attractive Investment Proposition
3.6 Competitive Landscape of Key Players in Hypercholesterolemia Drugs Market

Chapter 4 Global Hypercholesterolemia Drugs Market, by Drugs Class
4.1 Overview
4.2 Attractive Investment Proposition: Global Hypercholesterolemia Drugs Market, by Drugs Class
4.3 Top 3 Countries
4.4 HMG-CoA Reductase Inhibitors/ Statins
4.5 Bile Acid Sequestrants
4.6 Fibrates
4.7 Cholesterol Absorption Inhibitors
4.8 Other

Chapter 5 Global Hypercholesterolemia Drugs Market, By Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.2.1 North America Hypercholesterolemia Drugs Market, by Drugs Class, 2015- 2025 (US$)
5.2.2 North America Hypercholesterolemia Drugs Market, by Country, 2015- 2025 (US$)
5.3 Europe (U.K., Germany & Rest of Europe)
5.3.1 Europe Hypercholesterolemia Drugs Market, by Drugs Class, 2015- 2025 (US$)
5.3.2 Europe Hypercholesterolemia Drugs Market, by Country, 2015- 2025 (US$)
5.4 Asia Pacific (China, Japan and Rest of APAC)
5.4.1 Asia Pacific Hypercholesterolemia Drugs Market, by Drugs Class, 2015- 2025 (US$)
5.4.1 Asia Pacific Hypercholesterolemia Drugs Market, by Country, 2015- 2025 (US$)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.5.1 Latin America Hypercholesterolemia Drugs Market, by Drugs Class, 2015- 2025 (US$)
5.5.2 Latin America Hypercholesterolemia Drugs Market, by Country, 2015- 2025 (US$)
5.6 Middle East and Africa (GCC and Rest of MEA)
5.6.1 Middle East and Africa Hypercholesterolemia Drugs Market, by Drugs Class, 2015- 2025 (US$)
5.6.2 Middle East and Africa Hypercholesterolemia Drugs Market, by Country, 2015- 2025 (US$)

Chapter 6 Company Profiles
6.1 AbbVie Inc.
6.2 Aegerion Pharmaceuticals
6.3 Amgen Inc.
6.4 AstraZeneca
6.5 Eli Lilly and Company
6.6 Lupin Pharmaceuticals, Inc.
6.7 Merck & Co., Inc.
6.8 Pfizer Inc.
6.9 Sanofi S.A.
6.10 Shore Therapeutics, Inc.
6.11 Teva Pharmaceuticals

List of Figures

FIG. 1 Hypercholesterolemia Drugs Market: Research Methodology
FIG. 2 Global Hypercholesterolemia Drugs Market, by Drugs Class, 2016 (US$ Bn)
FIG. 3 Global Hypercholesterolemia Drugs Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition: Global Hypercholesterolemia Drugs Market, by Geography, 2016
FIG. 5 Attractive Investment Proposition: Global Hypercholesterolemia Drugs Market, by Drugs Class, 2016
FIG. 6 Global Hypercholesterolemia Drugs Market for HMG-CoA Reductase Inhibitors/ Statins, 2015 – 2025 (US$ Bn)
FIG. 7 Global Hypercholesterolemia Drugs Market for Bile Acid Sequestrants, 2015 – 2025 (US$ Bn)
FIG. 8 Global Hypercholesterolemia Drugs Market for Fibrates, 2015 – 2025 (US$ Bn)
FIG. 9 Global Hypercholesterolemia Drugs Market for Cholesterol Absorption Inhibitors, 2015 – 2025 (US$ Bn)
FIG. 10 Global Other Drugs in Hypercholesterolemia Drugs Market, 2015 – 2025 (US$ Bn)

List of Tables

TABLE 1 Market Positioning of Key Players in Global Hypercholesterolemia Drugs Market
TABLE 2 Global Hypercholesterolemia Drugs Market, by Drugs Class, 2015 – 2025 (US$ Bn)
TABLE 3 Top 3 Countries in Global Hypercholesterolemia Drugs Market, by Drugs Class 2015 – 2025 (US$ Bn)
TABLE 4 Global Hypercholesterolemia Drugs Market, by Geography, 2015 – 2025 (US$ Bn)
TABLE 5 North America Hypercholesterolemia Drugs Market, by Drugs Class, 2015-2025 (US$ Bn)
TABLE 6 North America Hypercholesterolemia Drugs Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 7 Europe Hypercholesterolemia Drugs Market, by Drugs Class, 2015-2025 (US$ Bn)
TABLE 8 Europe Hypercholesterolemia Drugs Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 9 Asia Pacific Hypercholesterolemia Drugs Market, by Drugs Class, 2015-2025 (US$ Bn)
TABLE 10 Asia Pacific Hypercholesterolemia Drugs Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 11 Latin America Hypercholesterolemia Drugs Market, by Drugs Class, 2015-2025 (US$ Bn)
TABLE 12 Latin America Hypercholesterolemia Drugs Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 13 Middle East and Africa Hypercholesterolemia Drugs Market, by Drugs Class, 2015-2025 (US$ Bn)
TABLE 14 Middle East and Africa Hypercholesterolemia Drugs Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 15 AbbVie Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 16 Aegerion Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 17 Amgen Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 18 AstraZeneca: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 19 Eli Lilly and Company: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 20 Lupin Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 21 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 22 Pfizer Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 23 Sanofi S.A.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 24 Shore Therapeutics, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 25 Teva Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)